核心观点公司发布公告,其GLP-1R 激动剂ASC30 在美国Ib 期临床试验取得积极成果。数据显示,前两个列队中ASC30 经安慰剂组校准后分别使体重下降4.2%和6.2%,并且安全性良好。我们认为,全球减重药物市场规模蓬勃成长,众多超重或肥胖成年人群急需创新药物来改善并提高生活质量,在此基础下,公司的两款药物ASC30、ASC47 均具备差异化设计方式,产品发展未来可期。事件公司发布公告,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.